Updated recommendations to minimise the risks of malignancy, major adverse cardiovascular events, serious infections, venous thromboembolism and mortality with use of Janus kinase inhibitors (JAKi)

Table of contents


This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.


Key facts

Medicine name
  • Cibinqo
  • Jyseleca
  • Olumiant
  • Rinvoq
  • Xeljanz
Active substance
  • Abrocitinib
  • filgotinib
  • Baricitinib
  • upadacitinib
  • Tofacitinib
Therapeutic area (MeSH)
  • Arthritis, Rheumatoid
  • Dermatitis, Atopic
Procedure number
EMEA/H-A20/1517/C/004214/0048; EMEA/H-A20/1517/C/005452/0003; EMEA/H-A20/1517/C/004085/0032; EMEA/H-A20/1517/C/004760/0017; EMEA/H-A20/1517/C/005113/0014
Regulatory outcome
DHPC type
Referral - Article 20 procedure
Referral name
Janus kinase inhibitors (JAKi)
Human ATC code
  • D11AH08
  • L04AA45
  • L04AA37
  • L04AA44
  • L04AA29
Dissemination date

How useful was this page?

Add your rating